One important unresolved issue is the limited evidence regarding concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists, a gap also acknowledged in European Society of Cardiology guidelines and Current guidelines prioritize SGLT2 inhibitors in patients with T2DM who have HF, chronic kidney disease, or elevated cardiovascular risk, while GLP-1 receptor agonists are emphasized for patients with obesity or established atherosclerotic cardiovascular disease [7]
Semaglutide GLP-1 operates as a GLP-1 (glucagon-like peptide-1) receptor agonist, which uses hormone mimicry to control appetite and reduce food intake
TNF alpha-blockers target the immune system and are used to treat rheumatoid arthritis and some other forms of inflammatory arthritis
What is glutathione and what does it really do in the body
Malhotra A, Ayappa I, Ayas N, et al
Your provider should evaluate contraindications and precautions, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, which are absolute contraindications to GLP-1 receptor agonists
